Moderna, Inc. (MRNA) Bundle
An Overview of Moderna, Inc. (MRNA)
General Summary of Moderna, Inc. (MRNA)
Moderna, Inc. is a biotechnology company founded in 2010, known for its pioneering work in messenger RNA (mRNA) technology. The company gained significant attention and market presence due to its development of the COVID-19 vaccine, mRNA-1273, which was authorized for emergency use in December 2020. By 2024, Moderna has expanded its portfolio to include a second commercial product, the RSV vaccine (mRNA-1345), approved in May 2024.
In 2024, Moderna has continued to leverage its mRNA platform to adapt its vaccines to evolving strains of viruses. The company reported net product sales of $1.8 billion for the third quarter of 2024, with the COVID-19 vaccine contributing $1.81 billion and the RSV vaccine generating $10 million.
Company's Financial Performance in the Latest Financial Reports
For the three months ended September 30, 2024, Moderna reported net product sales of $1.82 billion, marking a 4% increase compared to $1.76 billion in the same period of 2023. However, for the nine months ended September 30, 2024, total revenue decreased by $1.8 billion, or 44%, compared to the same period in 2023, primarily due to lower net product sales of the COVID-19 vaccine.
The following table summarizes Moderna's financial performance for the three and nine months ended September 30, 2024:
| Financial Metrics | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Net Product Sales | $1.82 billion | $1.76 billion | $2.17 billion | $3.88 billion |
| Total Revenue | $1.86 billion | $1.83 billion | $2.27 billion | $4.04 billion |
| Net Loss | $(2.44) billion | $(4.93) billion | $(2.44) billion | $(4.93) billion |
| Cost of Sales | $514 million | $2.24 billion | $725 million | $3.76 billion |
| Research & Development Expenses | $1.14 billion | $1.16 billion | $3.42 billion | $3.44 billion |
Operating expenses for the nine months ended September 30, 2024, totaled $4.97 billion, a decrease of 40% from $8.28 billion in the same period of 2023. The reduction in operating expenses was primarily due to lower costs associated with sales and marketing efforts as the company adjusts to a more seasonal market for its vaccines.
Introduction to Company as a Leader in the Industry
As of 2024, Moderna is recognized as a leading company in the biotechnology industry, particularly in the field of mRNA technology. The company has established itself through rapid vaccine development and deployment during the COVID-19 pandemic, setting a benchmark for speed and efficacy in vaccine development. Moderna's commitment to innovation is evident in its ongoing research and development of vaccines for various infectious diseases, including RSV and seasonal flu.
With a robust pipeline of investigational vaccines and therapies, Moderna continues to position itself as a key player in the biotech sector. The company's focus on leveraging its mRNA platform for future vaccines against a range of diseases underscores its potential for sustained growth and market leadership.
Mission Statement of Moderna, Inc. (MRNA)
Mission Statement of Moderna, Inc. (MRNA)
Moderna, Inc.'s mission statement emphasizes a commitment to delivering transformative medicines to improve patient outcomes. The company aims to leverage its innovative mRNA platform to develop a new class of vaccines and therapeutics for infectious diseases, cancer, and other serious health conditions.
Core Component 1: Innovation in mRNA Technology
Moderna's mission highlights its focus on innovation through mRNA technology. The company has pioneered the use of messenger RNA to instruct cells to produce proteins that can prevent or treat diseases. As of September 30, 2024, Moderna has two commercial products authorized for use: its COVID-19 vaccine and its RSV vaccine, which received FDA approval in May 2024 for adults aged 60 and older.
In the third quarter of 2024, Moderna recognized net product sales amounting to $1.82 billion, driven primarily by sales of its COVID-19 vaccine, which accounted for $1.81 billion. The company continues to invest in research and development, with R&D expenses totaling $3.42 billion for the nine months ended September 30, 2024.
Core Component 2: Commitment to Public Health
Moderna’s mission underscores its dedication to enhancing public health through accessible and effective vaccines. The company has engaged in multiple collaborations with government entities, including a partnership with the Biomedical Advanced Research and Development Authority (BARDA) that has provided up to $1.8 billion for the development of its COVID-19 vaccine. As of September 30, 2024, the remaining available funding from BARDA, net of revenue earned, stood at $70 million.
Additionally, Moderna has expanded its focus to include vaccines for respiratory viruses, with expectations of increased demand for its COVID-19 and RSV vaccines in seasonal campaigns. The company anticipates further reductions in net product sales for its COVID-19 vaccine in 2024, reflecting a shift to a more seasonal commercial model.
Core Component 3: Ethical Responsibility and Quality
Moderna's mission statement reflects a strong ethical responsibility towards quality and safety in its products. The company adheres to strict manufacturing standards, which are evidenced by its recent Drug Establishment License (DEL) from Health Canada for its Laval facility. This certification allows Moderna to produce drug substances compliant with safety and quality standards, supporting domestic manufacturing of mRNA vaccines.
As of September 30, 2024, Moderna reported total cash, cash equivalents, and investments amounting to $9.2 billion, reflecting a decrease of $4.1 billion from December 31, 2023. The company’s commitment to maintaining strong financial health is essential for ensuring the continuous development and distribution of its high-quality vaccines and therapeutics.
| Financial Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Net Product Sales | $1.82 billion | $1.76 billion | +4% |
| R&D Expenses | $3.42 billion | $3.44 billion | -1% |
| Cash and Cash Equivalents | $1.64 billion | $2.91 billion | -44% |
| Deferred Revenue | $443 million | $613 million | -27% |
Vision Statement of Moderna, Inc. (MRNA)
Vision Statement of Moderna, Inc. (MRNA)
Moderna, Inc. aims to deliver on its vision of harnessing the potential of mRNA technology to create a new class of transformative medicines. As of 2024, the company is focused on its strategic objectives that align with this vision.
Commitment to InnovationModerna's vision emphasizes a strong commitment to innovation, particularly in the field of mRNA therapeutics. The company has invested significantly in research and development, with expenses amounting to $3.4 billion for the nine months ended September 30, 2024, reflecting a decrease of 1% compared to the same period in 2023.
Expansion of Product PortfolioModerna's vision includes expanding its product portfolio beyond COVID-19 vaccines. As of September 30, 2024, the company has two commercial products authorized for use: the COVID-19 vaccine and the RSV vaccine, which was approved in May 2024. In the third quarter of 2024, Moderna reported net product sales of $1.8 billion, with $1.81 billion attributed to the COVID-19 vaccine and $10 million to the RSV vaccine.
Global Health ImpactModerna envisions a significant impact on global health through its innovative vaccines. The company has commenced sales of its RSV vaccine in the third quarter of 2024, targeting high-risk populations, and anticipates higher demand for its COVID-19 and RSV vaccines during the fall and winter seasons. The full-year net product sales for 2024 are expected to reflect a decline compared to 2023, as the market transitions to a seasonal model, indicating a shift in demand patterns.
Sustainability and EfficiencyIn alignment with its vision, Moderna is committed to sustainability and operational efficiency. The cost of sales for the three months ended September 30, 2024, was $514 million, a significant decrease of 77% compared to the same period in 2023. This reduction is attributed to strategic initiatives aimed at optimizing manufacturing operations and improving efficiency.
| Financial Metrics | 2024 (Nine Months Ended Sept 30) | 2023 (Nine Months Ended Sept 30) |
|---|---|---|
| Research and Development Expenses | $3.4 billion | $3.4 billion |
| Net Product Sales | $2.2 billion | $3.9 billion |
| Cost of Sales | $725 million | $3.7 billion |
| Net Loss | $2.4 billion | $4.7 billion |
Moderna's vision reflects its ambition to leverage mRNA technology for significant advancements in medicine while addressing global health needs. The company continues to innovate and adapt to changing market dynamics, positioning itself as a leader in the biotechnology industry.
Core Values of Moderna, Inc. (MRNA)
Core Value 1: Innovation
Innovation is a cornerstone of Moderna's operations, driving the development of cutting-edge mRNA technology to create transformative medicines and vaccines.
In 2024, Moderna has expanded its pipeline to include 36 development candidates across 45 programs, with 42 currently in clinical trials. The company’s mRNA platform enables rapid adaptation to emerging health threats, such as the newly updated COVID-19 vaccine targeting the KP.2 and JN.1 strains, which received FDA approval in September 2024.
Core Value 2: Integrity
Integrity underpins Moderna's commitment to ethical practices and transparency in its business operations and clinical trials.
In 2024, Moderna's financial disclosures reflect a net loss of $2.4 billion for the nine months ended September 30, demonstrating a commitment to honest reporting despite operational challenges. Furthermore, the company's agreements with the Biomedical Advanced Research and Development Authority (BARDA) have been fully exercised, amounting to a total award of approximately $1.8 billion.
Core Value 3: Collaboration
Collaboration fuels Moderna's growth and enhances its capabilities through strategic partnerships.
In March 2024, Moderna entered into a development and commercialization funding arrangement with Blackstone, committing to provide up to $750 million to support the development of mRNA-based influenza vaccines. Additionally, Moderna collaborates with Merck on personalized mRNA cancer vaccines, sharing costs and profits equally, which highlights the importance of collaborative efforts in advancing medical innovations.
Core Value 4: Commitment to Patients
Moderna is dedicated to addressing public health needs and delivering solutions that improve patient outcomes.
In 2024, the FDA approved Moderna's RSV vaccine, mRESVIA, for adults aged 60 years and older, marking a significant milestone in the company's efforts to combat infectious diseases. The company reported net product sales of $1.8 billion for the third quarter of 2024, showcasing its financial commitment to expanding access to its vaccines.
Core Value 5: Agility
Agility allows Moderna to respond swiftly to changing market conditions and emerging health threats.
In the third quarter of 2024, Moderna achieved net product sales of $1.8 billion, maintaining sales levels consistent with the same period in 2023 despite evolving market dynamics. The company’s ability to quickly adapt its COVID-19 vaccine in response to new variants exemplifies its agile approach.
| Core Value | Examples of Commitment | Financial Impact |
|---|---|---|
| Innovation | Expanded pipeline to 36 candidates, 42 in clinical trials | Net loss of $2.4 billion for nine months ended Sept 30, 2024 |
| Integrity | Transparent financial reporting and ethical practices | Total BARDA award of $1.8 billion |
| Collaboration | Partnership with Blackstone for $750 million funding | Shared costs with Merck on cancer vaccine development |
| Commitment to Patients | FDA approval of RSV vaccine for older adults | Net product sales of $1.8 billion in Q3 2024 |
| Agility | Quick adaptation of COVID-19 vaccine to new variants | Consistent sales levels despite market changes |
Moderna, Inc. (MRNA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Moderna, Inc. (MRNA) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Moderna, Inc. (MRNA)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Moderna, Inc. (MRNA)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.